Urovalve Bladder Management System Shows Early Promise in Clinical Trial
Urovalve announced promising early results this week in a multi-site clinical trial of its Surinate Bladder Management System.
news1
OneMedForum New York 2010: Key Days for Innovation in Healthcare
Though selected in order to give a platform to lesser recognized businesses, the companies presenting demonstrated the vast diversity of the healthcare and life science spaces.
Celgene Acquires Abraxis In $2.9 Billion Deal
Celgene has acquired Abraxis BioScience in a cash-and-stock deal valued at $2.9 billion, reports FierceBiotech.
Access Pharma’s Drug Delivery Technology Is a Stealth Asset
Access Pharma (OTC: ACCP.OB) provided an update today on the status of its cobalamin-based oral drug delivery product development programs.
[Video Profile] CoreSpine Technologies
One of the most important steps in spinal implant surgery is removing all nucleus material from the lumbar disc before inserting the implant. If any […]
An engineering approach to translational medicine
The mechanisms that drive disease have long confounded the medical industry. How much of a part does genetics play? How does the patient’s lifestyle influence his or her risk of developing cancer? What makes one patient respond favorably to a particular treatment, while another suffers severe side effects?
FDA draws criticism over Menaflex approval
The Food and Drug Administration is facing criticism following its controversial approval of a new device to treat knee injuries. The federal agency recently cleared […]
Brocair publishes new research on aesthetic device space
Brocair Partners recently published its latest research report on the aesthetic medical device market. This report contains a matrix of technologies provided by companies that […]
Glaucoma: the first neurodegenerative disease we can cure?
The possibility that Glaucoma could be a.) a neurological disease and b.) curable, suggested by a new study of the disease presented January 28th by […]
Spectranetics Releases 12-Month CELLO Study Data
Spectranetics has released 12-month follow-up data from its CELLO study. The data validates the strengths of the company’s Turbo-Booster as demonstrated by an excellent safety […]